Year |
Citation |
Score |
2024 |
Sánchez-Garrido MA, Serrano-López V, Ruiz-Pino F, Vázquez MJ, Rodríguez-Martín A, Torres E, Velasco I, Rodríguez AB, Chicano-Gálvez E, Mora-Ortiz M, Ohlsson C, Poutanen M, Pinilla L, Gaytán F, Douros JD, ... ... Finan B, et al. Superior metabolic improvement of polycystic ovary syndrome traits after GLP1-based multi-agonist therapy. Nature Communications. 15: 8498. PMID 39353946 DOI: 10.1038/s41467-024-52898-y |
0.601 |
|
2024 |
Sachs S, Götz A, Finan B, Feuchtinger A, DiMarchi RD, Döring Y, Weber C, Tschöp MH, Müller TD, Hofmann SM. Correction: GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease. Cardiovascular Diabetology. 23: 341. PMID 39267039 DOI: 10.1186/s12933-024-02407-8 |
0.563 |
|
2024 |
Zaykov AN, Gelfanov VM, Tagmose TM, Demozay D, Manfè V, Rohlfs R, Rivir M, Perez-Tilve D, Finan B, DiMarchi RD. Toward once-monthly insulin therapy synergy in two pharmacokinetic protractors: Fc-conjugation and fatty acid acylation. Rsc Chemical Biology. 5: 763-775. PMID 39092439 DOI: 10.1039/d4cb00078a |
0.784 |
|
2024 |
Petersen J, Ludwig MQ, Juozaityte V, Ranea-Robles P, Svendsen C, Hwang E, Kristensen AW, Fadahunsi N, Lund J, Breum AW, Mathiesen CV, Sachs L, Moreno-Justicia R, Rohlfs R, Ford JC, ... ... Finan B, et al. GLP-1-directed NMDA receptor antagonism for obesity treatment. Nature. PMID 38750368 DOI: 10.1038/s41586-024-07419-8 |
0.564 |
|
2024 |
Akindehin S, Liskiewicz A, Liskiewicz D, Bernecker M, Garcia-Caceres C, Drucker DJ, Finan B, Grandl G, Gutgesell R, Hofmann SM, Khalil A, Liu X, Cota P, Bakhti M, Czarnecki O, et al. Loss of GIPR in LEPR cells impairs glucose control by GIP and GIP:GLP-1 co-agonism without affecting body weight and food intake in mice. Molecular Metabolism. 83: 101915. PMID 38492844 DOI: 10.1016/j.molmet.2024.101915 |
0.581 |
|
2023 |
Liskiewicz A, Khalil A, Liskiewicz D, Novikoff A, Grandl G, Maity-Kumar G, Gutgesell RM, Bakhti M, Bastidas-Ponce A, Czarnecki O, Makris K, Lickert H, Feuchtinger A, Tost M, Coupland C, ... ... Finan B, et al. Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice. Nature Metabolism. PMID 37946085 DOI: 10.1038/s42255-023-00931-7 |
0.608 |
|
2023 |
Sachs S, Götz A, Finan B, Feuchtinger A, DiMarchi RD, Döring Y, Weber C, Tschöp MH, Müller TD, Hofmann SM. GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease. Cardiovascular Diabetology. 22: 217. PMID 37592302 DOI: 10.1186/s12933-023-01940-2 |
0.617 |
|
2023 |
Campbell JE, Müller TD, Finan B, DiMarchi RD, Tschöp MH, D'Alessio DA. GIPR/GLP-1R dual agonist therapies for diabetes and weight loss-chemistry, physiology, and clinical applications. Cell Metabolism. PMID 37591245 DOI: 10.1016/j.cmet.2023.07.010 |
0.638 |
|
2023 |
Wewer Albrechtsen NJ, Holst JJ, Cherrington AD, Finan B, Gluud LL, Dean ED, Campbell JE, Bloom SR, Tan TM, Knop FK, Müller TD. 100 years of glucagon and 100 more. Diabetologia. 66: 1378-1394. PMID 37367959 DOI: 10.1007/s00125-023-05947-y |
0.359 |
|
2023 |
El K, Douros JD, Willard FS, Novikoff A, Sargsyan A, Perez-Tilve D, Wainscott DB, Yang B, Chen A, Wothe D, Coupland C, Tschöp MH, Finan B, D'Alessio DA, Sloop KW, et al. The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets. Nature Metabolism. PMID 37277609 DOI: 10.1038/s42255-023-00811-0 |
0.387 |
|
2022 |
Yang B, Gelfanov VM, El K, Chen A, Rohlfs R, DuBois B, Kruse Hansen AM, Perez-Tilve D, Knerr PJ, D'Alessio D, Campbell JE, Douros JD, Finan B. Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems. Molecular Metabolism. 101638. PMID 36400403 DOI: 10.1016/j.molmet.2022.101638 |
0.389 |
|
2022 |
Sekar R, Motzler K, Kwon Y, Novikoff A, Jülg J, Najafi B, Wang S, Warnke AL, Seitz S, Hass D, Gancheva S, Kahl S, Yang B, Finan B, Schwarz K, et al. Vps37a regulates hepatic glucose production by controlling glucagon receptor localization to endosomes. Cell Metabolism. PMID 36243006 DOI: 10.1016/j.cmet.2022.09.022 |
0.32 |
|
2022 |
Quarta C, Stemmer K, Novikoff A, Yang B, Klingelhuber F, Harger A, Bakhti M, Bastidas-Ponce A, Baugé E, Campbell JE, Capozzi M, Clemmensen C, Collden G, Cota P, Douros J, ... ... Finan B, et al. GLP-1-mediated delivery of tesaglitazar improves obesity and glucose metabolism in male mice. Nature Metabolism. 4: 1071-1083. PMID 35995995 DOI: 10.1038/s42255-022-00617-6 |
0.608 |
|
2022 |
Kim T, Nason S, Antipenko J, Finan B, Shalev A, DiMarchi R, Habegger KM. Hepatic TORC2 Signaling Facilitates Acute Glucagon-Receptor Enhancement of Insulin-Stimulated Glucose Homeostasis in Mice. Diabetes. PMID 35877180 DOI: 10.2337/db21-1018 |
0.584 |
|
2022 |
Knerr PJ, Mowery SA, Douros JD, Premdjee B, Hjøllund KR, He Y, Kruse Hansen AM, Olsen AK, Perez-Tilve D, DiMarchi RD, Finan B. Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice. Molecular Metabolism. 101533. PMID 35809773 DOI: 10.1016/j.molmet.2022.101533 |
0.671 |
|
2021 |
He R, Mowery SA, Chabenne J, Finan B, Mayer JP, DiMarchi RD. A Facile Procedure for One-Pot Stable Conjugation of Two Proglucagon Cysteine-Containing Peptide Analogs. Frontiers in Endocrinology. 12: 693958. PMID 34484114 DOI: 10.3389/fendo.2021.693958 |
0.766 |
|
2021 |
Yang B, Gelfanov VM, Perez-Tilve D, DuBois B, Rohlfs R, Levy J, Douros JD, Finan B, Mayer JP, DiMarchi RD. Optimization of Truncated Glucagon Peptides to Achieve Selective, High Potency, Full Antagonists. Journal of Medicinal Chemistry. PMID 33821647 DOI: 10.1021/acs.jmedchem.0c02069 |
0.582 |
|
2021 |
Zhang Q, Delessa CT, Augustin R, Bakhti M, Colldén G, Drucker DJ, Feuchtinger A, Caceres CG, Grandl G, Harger A, Herzig S, Hofmann S, Holleman CL, Jastroch M, Keipert S, ... ... Finan B, et al. The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling. Cell Metabolism. PMID 33571454 DOI: 10.1016/j.cmet.2021.01.015 |
0.612 |
|
2021 |
Novikoff A, O'Brien SL, Bernecker M, Grandl G, Kleinert M, Knerr PJ, Stemmer K, Klingenspor M, Zeigerer A, DiMarchi R, Tschöp MH, Finan B, Calebiro D, Müller TD. Spatiotemporal GLP-1 and GIPR receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists. Molecular Metabolism. 101181. PMID 33556643 DOI: 10.1016/j.molmet.2021.101181 |
0.508 |
|
2021 |
Nason SR, Antipenko JP, Presedo N, Cunningham SE, Pierre TH, Kim T, Paul JR, Holleman CL, Young ME, Gamble KL, Finan B, DiMarchi R, Hunter CS, Kharitonenkov A, Habegger KM. Glucagon-receptor signaling regulates weight loss via central KLB receptor complexes. Jci Insight. PMID 33411693 DOI: 10.1172/jci.insight.141323 |
0.601 |
|
2020 |
Sachs S, Bastidas-Ponce A, Tritschler S, Bakhti M, Böttcher A, Sánchez-Garrido MA, Tarquis-Medina M, Kleinert M, Fischer K, Jall S, Harger A, Bader E, Roscioni S, Ussar S, Feuchtinger A, ... ... Finan B, et al. Author Correction: Targeted pharmacological therapy restores β-cell function for diabetes remission. Nature Metabolism. 2: 380. PMID 33820985 DOI: 10.1038/s42255-020-0201-1 |
0.469 |
|
2020 |
Finan B, Parlee SD, Yang B. Nuclear Hormone and Peptide Hormone Therapeutics for NAFLD and NASH. Molecular Metabolism. 101153. PMID 33359400 DOI: 10.1016/j.molmet.2020.101153 |
0.374 |
|
2020 |
Zizzari P, He R, Falk S, Bellocchio L, Allard C, Clark S, Lesté-Lasserre T, Marsicano G, Clemmensen C, Perez-Tilve D, Finan B, Cota D, Quarta C. CB1 and GLP-1 Receptors Cross-Talk Provides New Therapies for Obesity. Diabetes. PMID 33144338 DOI: 10.2337/db20-0162 |
0.435 |
|
2020 |
Pan J, Parlee SD, Brunel FM, Li P, Lu W, Perez-Tilve D, Liu F, Finan B, Kharitonenkov A, DiMarchi RD. Optimization of Peptide Inhibitors of β-Klotho as Antagonists of Fibroblast Growth Factors 19 and 21. Acs Pharmacology & Translational Science. 3: 978-986. PMID 33073195 DOI: 10.1021/acsptsci.0c00100 |
0.582 |
|
2020 |
Sachs S, Niu L, Geyer P, Jall S, Kleinert M, Feuchtinger A, Stemmer K, Brielmeier M, Finan B, DiMarchi RD, Tschöp MH, Albrechtsen NW, Mann M, Müller TD, Hofmann SM. Plasma proteome profiles treatment efficacy of incretin dual agonism in diet-induced obese female and male mice. Diabetes, Obesity & Metabolism. PMID 33001570 DOI: 10.1111/dom.14215 |
0.612 |
|
2020 |
Sachs S, Bastidas-Ponce A, Tritschler S, Bakhti M, Böttcher A, Sánchez-Garrido MA, Tarquis-Medina M, Kleinert M, Fischer K, Jall S, Harger A, Bader E, Roscioni S, Ussar S, Feuchtinger A, ... ... Finan B, et al. Targeted pharmacological therapy restores β-cell function for diabetes remission. Nature Metabolism. 2: 192-209. PMID 32694693 DOI: 10.1038/s42255-020-0171-3 |
0.507 |
|
2020 |
Stemmer K, Finan B, DiMarchi RD, Tschöp MH, Müller TD. Insights into incretin-based therapies for treatment of diabetic dyslipidemia. Advanced Drug Delivery Reviews. PMID 32485206 DOI: 10.1016/J.Addr.2020.05.008 |
0.655 |
|
2020 |
Fischer K, Fenzl A, Liu D, Dyar KA, Kleinert M, Brielmeier M, Clemmensen C, Fedl A, Finan B, Gessner A, Jastroch M, Huang J, Keipert S, Klingenspor M, Brüning JC, et al. The scaffold protein p62 regulates adaptive thermogenesis through ATF2 nuclear target activation. Nature Communications. 11: 2306. PMID 32385399 DOI: 10.1038/S41467-020-16230-8 |
0.321 |
|
2020 |
Svendsen B, Capozzi ME, Nui J, Hannou SA, Finan B, Naylor J, Ravn P, D'Alessio DA, Campbell JE. Pharmacological antagonism of the incretin system protects against diet-induced obesity. Molecular Metabolism. 32: 44-55. PMID 32029229 DOI: 10.1016/J.Molmet.2019.11.018 |
0.556 |
|
2020 |
Capozzi ME, Coch RW, Koech J, Astapova II, Wait JB, Encisco SE, Douros JD, El K, Finan B, Sloop KW, Herman MA, D'Alessio DA, Campbell JE. The Limited Role of Glucagon for Ketogenesis During Fasting or in Response to SGLT2 Inhibition. Diabetes. PMID 32005706 DOI: 10.2337/Db19-1216 |
0.405 |
|
2020 |
Hofmann SM, Albrechtsen NJW, Tschöp MH, Feuchtinger A, Brielmeier M, Finan B, Dimarchi R, Kleinert M, Sachs S, Müller TD, Stemmer K, Mann M. 936-P: Plasma Proteomic Profiling Delineates Treatment Efficacy of a GLP-1/GIP Coagonist in Female and Male Mice Diabetes. 69. DOI: 10.2337/Db20-936-P |
0.64 |
|
2020 |
Kim T, Nason SR, Antipenko J, Presedo N, Finan B, DiMarchi RD, Habegger KM. SAT-655 Bile Acid Sequestration Synergistically Accelerates Glucagon Receptor-Stimulated Body Weight Loss in Diet-Induced Obese Mice Journal of the Endocrine Society. 4. DOI: 10.1210/Jendso/Bvaa046.1106 |
0.413 |
|
2020 |
Presedo N, Kim T, Nason SR, Antipenko J, Finan B, DiMarchi R, Habegger K. Glucagon Regulates Energy Balance via FGF21 Signaling in the Brain The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.03065 |
0.509 |
|
2019 |
Knerr PJ, Mowery SA, Finan B, Perez-Tilve D, Tschöp MH, DiMarchi RD. Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates. Peptides. 170225. PMID 31786282 DOI: 10.1016/J.Peptides.2019.170225 |
0.673 |
|
2019 |
Müller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ, Langhans W, Meier JJ, Nauck MA, Perez-Tilve D, et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 30: 72-130. PMID 31767182 DOI: 10.1016/J.Molmet.2019.09.010 |
0.511 |
|
2019 |
Jall S, Finan B, Collden G, Fischer K, Dong X, Tschöp MH, Müller TD, Clemmensen C. Corrigendum to "Pirt deficiency has subtle female-specific effects on energy and glucose metabolism in mice" [Molecular Metabolism 23 (2019) 75-81]. Molecular Metabolism. 30: 264. PMID 31767177 DOI: 10.1016/J.Molmet.2019.11.002 |
0.397 |
|
2019 |
Nason SR, Kim T, Antipenko JP, Finan B, DiMarchi R, Hunter CS, Habegger KM. Glucagon-Receptor Signaling Reverses Hepatic Steatosis Independent of Leptin Receptor Expression. Endocrinology. PMID 31673703 DOI: 10.1210/Endocr/Bqz013 |
0.6 |
|
2019 |
Zaykov AN, Gelfanov VM, Perez-Tilve D, Finan B, DiMarchi RD. Insulin-like peptide 5 fails to improve metabolism or body weight in obese mice. Peptides. 120: 170116. PMID 31348991 DOI: 10.1016/J.Peptides.2019.170116 |
0.825 |
|
2019 |
Brunel FM, Mayer JP, Gelfanov VM, Zaykov AN, Finan B, Perez-Tilve D, DiMarchi RD. A disulfide-scan of insulin by [3+1] methodology exhibits site-specific influence on bioactivity. Acs Chemical Biology. PMID 31343157 DOI: 10.1021/Acschembio.9B00420 |
0.788 |
|
2019 |
Capozzi ME, Wait JB, Koech J, Gordon AN, Coch RW, Svendsen B, Finan B, D'Alessio DA, Campbell JE. Glucagon lowers glycemia when β-cells are active. Jci Insight. 5. PMID 31335319 DOI: 10.1172/Jci.Insight.129954 |
0.413 |
|
2019 |
Finan B, Capozzi ME, Campbell JE. Repositioning Glucagon Action in the Physiology and Pharmacology of Diabetes. Diabetes. PMID 31178432 DOI: 10.2337/Dbi19-0004 |
0.44 |
|
2019 |
He R, Finan B, Mayer JP, DiMarchi RD. Peptide Conjugates with Small Molecules Designed to Enhance Efficacy and Safety. Molecules (Basel, Switzerland). 24. PMID 31091786 DOI: 10.3390/Molecules24101855 |
0.576 |
|
2019 |
Décarie-Spain L, Fisette A, Zhu Z, Yang B, DiMarchi RD, Tschöp MH, Finan B, Fulton S, Clemmensen C. GLP-1/dexamethasone inhibits food reward without inducing mood and memory deficits in mice. Neuropharmacology. PMID 30946847 DOI: 10.1016/J.Neuropharm.2019.03.035 |
0.621 |
|
2019 |
Ratner C, He Z, Grunddal KV, Skov LJ, Hartmann B, Zhang F, Feuchtinger A, Bjerregaard A, Christoffersen C, Tschöp MH, Finan B, DiMarchi RD, Leinninger GM, Williams KW, Clemmensen C, et al. Long Acting Neurotensin Synergizes with Liraglutide to Reverse Obesity Through a Melanocortin-Dependent Pathway. Diabetes. PMID 30936142 DOI: 10.2337/Db18-1009 |
0.646 |
|
2019 |
Jall S, Finan B, Collden G, Fischer K, Dong X, Tschöp MH, Müller TD, Clemmensen C. Pirt deficiency has subtle female-specific effects on energy and glucose metabolism in mice. Molecular Metabolism. PMID 30902502 DOI: 10.1016/J.Molmet.2019.02.011 |
0.414 |
|
2019 |
Müller TD, Clemmensen C, Finan B, DiMarchi RD, Tschöp MH. Anti-Obesity Therapy: from Rainbow Pills to Polyagonists. Pharmacological Reviews. 70: 712-746. PMID 30087160 DOI: 10.1124/Pr.117.014803 |
0.486 |
|
2019 |
KIM T, ANTIPENKO JP, NASON S, PRESEDO N, VAN DER POL WJ, FINAN B, DIMARCHI R, MORROW CD, HABEGGER KM. 1965-P: Glucagon Receptor Agonism Stimulates Body Weight Loss in Antibiotic Treatment in Obese Mice Diabetes. 68: 1965-P. DOI: 10.2337/Db19-1965-P |
0.641 |
|
2019 |
Nason S, Kim T, Antipenko JP, Finan B, Dimarchi R, Habegger KM. 1870-P: Glucagon-Receptor Signaling Reverses Hepatic Steatosis Independent of Leptin Receptor Expression Diabetes. 68. DOI: 10.2337/Db19-1870-P |
0.605 |
|
2019 |
Kim T, Nason S, Antipenko J, Presedo N, Finan B, DiMarchi R, Habegger K. OR28-5 Bile Acid Sequestration Accelerates Glucagon Receptor-Mediated Body Weight Loss in Obese Mice Journal of the Endocrine Society. 3. DOI: 10.1210/Js.2019-Or28-5 |
0.635 |
|
2018 |
Mroz PA, Finan B, Gelfanov V, Yang B, Tschöp MH, DiMarchi RD, Perez-Tilve D. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism. Molecular Metabolism. PMID 30578168 DOI: 10.1016/J.Molmet.2018.12.001 |
0.624 |
|
2018 |
Clemmensen C, Jall S, Kleinert M, Quarta C, Gruber T, Reber J, Sachs S, Fischer K, Feuchtinger A, Karlas A, Simonds SE, Grandl G, Loher D, Sanchez-Quant E, Keipert S, ... ... Finan B, et al. Publisher Correction: Coordinated targeting of cold and nicotinic receptors synergistically improves obesity and type 2 diabetes. Nature Communications. 9: 4975. PMID 30459311 DOI: 10.1038/S41467-018-07479-1 |
0.341 |
|
2018 |
Clemmensen C, Finan B, Müller TD, DiMarchi RD, Tschöp MH, Hofmann SM. Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases. Nature Reviews. Endocrinology. PMID 30446744 DOI: 10.1038/S41574-018-0118-X |
0.662 |
|
2018 |
Clemmensen C, Jall S, Kleinert M, Quarta C, Gruber T, Reber J, Sachs S, Fischer K, Feuchtinger A, Karlas A, Simonds SE, Grandl G, Loher D, Sanchez-Quant E, Keipert S, ... ... Finan B, et al. Coordinated targeting of cold and nicotinic receptors synergistically improves obesity and type 2 diabetes. Nature Communications. 9: 4304. PMID 30353008 DOI: 10.1038/S41467-018-06769-Y |
0.519 |
|
2018 |
Khajavi N, Finan B, Kluth O, Müller TD, Mergler S, Schulz A, Kleinau G, Scheerer P, Schürmann A, Gudermann T, Tschöp MH, Krude H, DiMarchi RD, Biebermann H. An incretin-based tri-agonist promotes superior insulin secretion from murine pancreatic islets via PLC activation. Cellular Signalling. 51: 13-22. PMID 30055232 DOI: 10.1016/J.Cellsig.2018.07.006 |
0.611 |
|
2018 |
Renner S, Blutke A, Dobenecker B, Dhom G, Müller TD, Finan B, Clemmensen C, Bernau M, Novak I, Rathkolb B, Senf S, Zöls S, Roth M, Götz A, Hofmann SM, et al. Metabolic syndrome and extensive adipose tissue inflammation in morbidly obese Göttingen minipigs. Molecular Metabolism. PMID 30017782 DOI: 10.1016/J.Molmet.2018.06.015 |
0.608 |
|
2018 |
Guo Z, Sahu BS, He R, Finan B, Cero C, Verardi R, Razzoli M, Veglia G, Di Marchi RD, Miles JM, Bartolomucci A. Clearance kinetics of the VGF-derived neuropeptide TLQP-21. Neuropeptides. PMID 29958697 DOI: 10.1016/J.Npep.2018.06.003 |
0.303 |
|
2018 |
Kim T, Nason S, Holleman C, Pepin M, Wilson L, Berryhill TF, Wende AR, Steele C, Young ME, Barnes S, Drucker DJ, Finan B, DiMarchi R, Perez-Tilve D, Tschoep M, et al. Glucagon-receptor Signaling Regulates Energy Metabolism Via Hepatic Farnesoid X Receptor and Fibroblast Growth Factor 21. Diabetes. PMID 29925501 DOI: 10.2337/Db17-1502 |
0.645 |
|
2018 |
Capozzi ME, DiMarchi RD, Tschöp MH, Finan B, Campbell JE. Targeting the Incretin/Glucagon System with Triagonists to Treat Diabetes. Endocrine Reviews. PMID 29905825 DOI: 10.1210/Er.2018-00117 |
0.656 |
|
2018 |
Agrawal A, Parlee S, Perez-Tilve D, Li P, Pan J, Mroz PA, Kruse Hansen AM, Andersen B, Finan B, Kharitonenkov A, DiMarchi RD. Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity. Molecular Metabolism. PMID 29789271 DOI: 10.1016/J.Molmet.2018.05.003 |
0.563 |
|
2018 |
KIM T, NASON S, ANTIPENKO JP, VESTRI CS, SMITH-JOHNSTON K, PEPIN ME, WENDE AR, FINAN B, DIMARCHI R, PEREZ-TILVE D, MOELLERING DR, HABEGGER KM. Glucagon-Receptor Signaling Regulates Mitochondrial Bioenergetics via Hepatic Farnesol X Receptor Diabetes. 67: 1978-P. DOI: 10.2337/Db18-1978-P |
0.6 |
|
2017 |
Knerr PJ, Finan B, Gelfanov V, Perez-Tilve D, Tschöp MH, DiMarchi RD. Optimization of peptide-based polyagonists for treatment of diabetes and obesity. Bioorganic & Medicinal Chemistry. PMID 29153547 DOI: 10.1016/J.Bmc.2017.10.047 |
0.626 |
|
2017 |
Quarta C, Clemmensen C, Zhu Z, Yang B, Joseph SS, Lutter D, Yi CX, Graf E, García-Cáceres C, Legutko B, Fischer K, Brommage R, Zizzari P, Franklin BS, Krueger M, ... ... Finan B, et al. Molecular Integration of Incretin and Glucocorticoid Action Reverses Immunometabolic Dysfunction and Obesity. Cell Metabolism. PMID 28943448 DOI: 10.1016/J.Cmet.2017.08.023 |
0.698 |
|
2017 |
Jall S, Sachs S, Clemmensen C, Finan B, Neff F, DiMarchi RD, Tschöp MH, Müller TD, Hofmann SM. Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice. Molecular Metabolism. 6: 440-446. PMID 28462078 DOI: 10.1016/J.Molmet.2017.02.002 |
0.682 |
|
2017 |
Fischer K, Ruiz HH, Jhun K, Finan B, Oberlin DJ, van der Heide V, Kalinovich AV, Petrovic N, Wolf Y, Clemmensen C, Shin AC, Divanovic S, Brombacher F, Glasmacher E, Keipert S, et al. Alternatively activated macrophages do not synthesize catecholamines or contribute to adipose tissue adaptive thermogenesis. Nature Medicine. PMID 28414329 DOI: 10.1038/Nm.4316 |
0.313 |
|
2017 |
Müller TD, Finan B, Clemmensen C, DiMarchi RD, Tschöp MH. The New Biology and Pharmacology of Glucagon. Physiological Reviews. 97: 721-766. PMID 28275047 DOI: 10.1152/Physrev.00025.2016 |
0.479 |
|
2016 |
Finan B, Clemmensen C, Zhu Z, Stemmer K, Gauthier K, Müller L, De Angelis M, Moreth K, Neff F, Perez-Tilve D, Fischer K, Lutter D, Sánchez-Garrido MA, Liu P, Tuckermann J, et al. Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease. Cell. PMID 27720451 DOI: 10.1016/J.Cell.2016.09.014 |
0.634 |
|
2016 |
Sánchez-Garrido MA, Habegger KM, Clemmensen C, Holleman C, Müller TD, Perez-Tilve D, Li P, Agrawal AS, Finan B, Drucker DJ, Tschöp MH, DiMarchi RD, Kharitonenkov A. Fibroblast activation protein (FAP) as a novel metabolic target. Molecular Metabolism. 5: 1015-24. PMID 27689014 DOI: 10.1016/J.Molmet.2016.07.003 |
0.57 |
|
2016 |
Vogel H, Wolf S, Rabasa C, Rodriguez-Pacheco F, Babaei CS, Stöber F, Goldschmidt J, DiMarchi RD, Finan B, Tschöp MH, Dickson SL, Schürmann A, Skibicka KP. GLP-1 and estrogen conjugate acts in the supramammillary nucleus to reduce food-reward and body weight. Neuropharmacology. PMID 27496691 DOI: 10.1016/J.Neuropharm.2016.07.039 |
0.583 |
|
2016 |
Tschöp MH, Finan B, Clemmensen C, Gelfanov V, Perez-Tilve D, Müller TD, DiMarchi RD. Unimolecular Polypharmacy for Treatment of Diabetes and Obesity. Cell Metabolism. 24: 51-62. PMID 27411008 DOI: 10.1016/J.Cmet.2016.06.021 |
0.621 |
|
2016 |
Finan B, Müller TD, Clemmensen C, Perez-Tilve D, Tschöp MH. Reappraisal of GIP Pharmacology for Metabolic Diseases. Trends in Molecular Medicine. PMID 27038883 DOI: 10.1016/J.Molmed.2016.03.005 |
0.515 |
|
2016 |
Kabra DG, Pfuhlmann K, García-Cáceres C, Schriever SC, Casquero García V, Kebede AF, Fuente-Martin E, Trivedi C, Heppner K, Uhlenhaut NH, Legutko B, Kabra UD, Gao Y, Yi CX, Quarta C, ... ... Finan B, et al. Hypothalamic leptin action is mediated by histone deacetylase 5. Nature Communications. 7: 10782. PMID 26923837 DOI: 10.1038/Ncomms10782 |
0.413 |
|
2015 |
Finan B, Clemmensen C, Müller TD. Emerging opportunities for the treatment of metabolic diseases: Glucagon-like peptide-1 based multi-agonists. Molecular and Cellular Endocrinology. PMID 26151488 DOI: 10.1016/J.Mce.2015.07.003 |
0.478 |
|
2015 |
Clemmensen C, Müller TD, Finan B, Tschöp MH, DiMarchi R. Current and Emerging Treatment Options in Diabetes Care. Handbook of Experimental Pharmacology. PMID 25903416 DOI: 10.1007/164_2015_7 |
0.588 |
|
2015 |
Clemmensen C, Finan B, Fischer K, Tom RZ, Legutko B, Sehrer L, Heine D, Grassl N, Meyer CW, Henderson B, Hofmann SM, Tschöp MH, Van der Ploeg LH, Müller TD. Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice. Embo Molecular Medicine. 7: 288-98. PMID 25652173 DOI: 10.15252/Emmm.201404508 |
0.513 |
|
2015 |
Schwenk RW, Baumeier C, Finan B, Kluth O, Brauer C, Joost HG, DiMarchi RD, Tschöp MH, Schürmann A. GLP-1-oestrogen attenuates hyperphagia and protects from beta cell failure in diabetes-prone New Zealand obese (NZO) mice. Diabetologia. 58: 604-14. PMID 25527001 DOI: 10.1007/S00125-014-3478-3 |
0.602 |
|
2015 |
Finan B, Yang B, Ottaway N, Smiley DL, Ma T, Clemmensen C, Chabenne J, Zhang L, Habegger KM, Fischer K, Campbell JE, Sandoval D, Seeley RJ, Bleicher K, Uhles S, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nature Medicine. 21: 27-36. PMID 25485909 DOI: 10.1038/Nm.3761 |
0.824 |
|
2015 |
Müller TD, Clemmensen C, Finan B, Dimarchi RD, Tschöp MH. Novel combinatorial therapies involving leptin: Opportunities for mechanistic advances and therapeutic translation in human diseases Leptin: Regulation and Clinical Applications. 267-279. DOI: 10.1007/978-3-319-09915-6_21 |
0.477 |
|
2014 |
Fischer K, Finan B, Clemmensen C, van der Ploeg LH, Tschöp MH, Müller TD. The Pentapeptide RM-131 Promotes Food Intake and Adiposity in Wildtype Mice but Not in Mice Lacking the Ghrelin Receptor. Frontiers in Nutrition. 1: 31. PMID 25988130 DOI: 10.3389/Fnut.2014.00031 |
0.458 |
|
2014 |
Morselli E, Fuente-Martin E, Finan B, Kim M, Frank A, Garcia-Caceres C, Navas CR, Gordillo R, Neinast M, Kalainayakan SP, Li DL, Gao Y, Yi CX, Hahner L, Palmer BF, et al. Hypothalamic PGC-1α protects against high-fat diet exposure by regulating ERα. Cell Reports. 9: 633-45. PMID 25373903 DOI: 10.1016/J.Celrep.2014.09.025 |
0.382 |
|
2014 |
Cansell C, Castel J, Denis RG, Rouch C, Delbes AS, Martinez S, Mestivier D, Finan B, Maldonado-Aviles JG, Rijnsburger M, Tschöp MH, DiLeone RJ, Eckel RH, la Fleur SE, Magnan C, et al. Dietary triglycerides act on mesolimbic structures to regulate the rewarding and motivational aspects of feeding. Molecular Psychiatry. 19: 1095-105. PMID 24732670 DOI: 10.1038/Mp.2014.31 |
0.317 |
|
2014 |
Clemmensen C, Chabenne J, Finan B, Sullivan L, Fischer K, Küchler D, Sehrer L, Ograjsek T, Hofmann SM, Schriever SC, Pfluger PT, Pinkstaff J, Tschöp MH, Dimarchi R, Müller TD. GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet. Diabetes. 63: 1422-7. PMID 24379349 DOI: 10.2337/Db13-1609 |
0.81 |
|
2014 |
Schwenk RW, Baumeier C, Finan B, Kluth O, Brauer C, Joost HG, DiMarchi RD, Tschöp MH, Schürmann A. GLP-1–oestrogen attenuates hyperphagia and protects from beta cell failure in diabetes-prone New Zealand obese (NZO) mice Diabetologia. 58: 604-614. DOI: 10.1007/s00125-014-3478-3 |
0.544 |
|
2013 |
Finan B, Ma T, Ottaway N, Müller TD, Habegger KM, Heppner KM, Kirchner H, Holland J, Hembree J, Raver C, Lockie SH, Smiley DL, Gelfanov V, Yang B, Hofmann S, et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans Science Translational Medicine. 5. PMID 24174327 DOI: 10.1126/Scitranslmed.3007218 |
0.703 |
|
2013 |
Fuente-Martin E, Garcia-Caceres C, Morselli E, Clegg DJ, Chowen JA, Finan B, Brinton RD, Tschöp MH. Estrogen, astrocytes and the neuroendocrine control of metabolism. Reviews in Endocrine & Metabolic Disorders. 14: 331-8. PMID 24009071 DOI: 10.1007/S11154-013-9263-7 |
0.404 |
|
2013 |
Müller TD, Müller A, Yi CX, Habegger KM, Meyer CW, Gaylinn BD, Finan B, Heppner K, Trivedi C, Bielohuby M, Abplanalp W, Meyer F, Piechowski CL, Pratzka J, Stemmer K, et al. The orphan receptor Gpr83 regulates systemic energy metabolism via ghrelin-dependent and ghrelin-independent mechanisms. Nature Communications. 4: 1968. PMID 23744028 DOI: 10.1038/Ncomms2968 |
0.669 |
|
2013 |
Müller TD, Lee SJ, Jastroch M, Kabra D, Stemmer K, Aichler M, Abplanalp B, Ananthakrishnan G, Bhardwaj N, Collins S, Divanovic S, Endele M, Finan B, Gao Y, Habegger KM, et al. p62 links β-adrenergic input to mitochondrial function and thermogenesis. The Journal of Clinical Investigation. 123: 469-78. PMID 23257354 DOI: 10.1172/Jci64209 |
0.325 |
|
2013 |
Müller T, Müller A, Habegger K, Yi C, Meyer C, Gaylinn B, Finan B, Heppner K, Trivedi C, Bielohuby M, Abplanalp W, Meyer F, Piechowski C, Pratzka J, Stemmer K, et al. The orphan receptor GPR83 regulates systemic energy metabolism via ghrelin-dependent and -independent mechanisms Experimental and Clinical Endocrinology & Diabetes. 121. DOI: 10.1055/S-0033-1336629 |
0.574 |
|
2012 |
Finan B, Yang B, Ottaway N, Stemmer K, Müller TD, Yi CX, Habegger K, Schriever SC, García-Cáceres C, Kabra DG, Hembree J, Holland J, Raver C, Seeley RJ, Hans W, et al. Targeted estrogen delivery reverses the metabolic syndrome. Nature Medicine. 18: 1847-56. PMID 23142820 DOI: 10.1038/Nm.3009 |
0.682 |
|
2012 |
Nogueiras R, Habegger KM, Chaudhary N, Finan B, Banks AS, Dietrich MO, Horvath TL, Sinclair DA, Pfluger PT, Tschöp MH. Sirtuin 1 and sirtuin 3: physiological modulators of metabolism. Physiological Reviews. 92: 1479-514. PMID 22811431 DOI: 10.1152/Physrev.00022.2011 |
0.395 |
|
Show low-probability matches. |